Clinical trials: Nonalcoholic Fatty Liver
NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
- Trial name
- NCT06528314
- Testing
- Efruxifermin
- Where
- 345 sites in United States, Argentina and 19 more
- Volunteers
- 2,150 people
- Sponsor
- Akero Therapeutics, Inc
NAFLD, Alcoholic Hepatitis
EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication?
Liver biopsy would be done by Endoscopic Ultrasound using Acquire needle.
- Trial name
- NCT04235855
- Testing
- Endoscopic USG guided Liver biopsy, Percutaneous Liver Biopsy
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Asian Institute of Gastroenterology, India
NON-ALCOHOLIC STEATOHEPATITIS
Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH
A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT06054815
- Testing
- DA-1241, Sitagliptin
- Where
- 18 sites in United States
- Volunteers
- 109 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Non-Alcoholic Fatty Liver Disease, Immune Response
The Role of Immune Semaphorins in NAFLD
To goal is to identify semaphorins that are associated with NAFLD and to investigate their relationship with variable degrees of steatosis and fibrosis.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Immune Response, Biomarkers, Liver Fibrosis
- Trial name
- SepsisFAT (NCT04573543)
- Testing
- Evaluation of the degree of fibrosis and steatosis, Screening for the components of metabolic syndrome, Measurement of serum semaphorin concentrations
- Where
- Croatia
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University Hospital for Infectious Diseases, Croatia
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease
Ultrasound Method to Measure Fibrosis of the Liver in Children
HYPOTHESIS: The investigators hypothesize that sonoelastography (SE) provide accurate quantitative measurements that can be used to stage liver fibrosis in pediatric patients with chronic liver disease.
- Conditions
- Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, HCV Coinfection, HBV
- Trial name
- NCT02086708
- Testing
- Shear Wave sonoelastography
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
NAFLD, Overweight and Obesity
The Acute Effects of Eucaloric and Hypocaloric Carbohydrate Restriction on Liver Fat Content and Metabolism in Obese Individuals
The primary aim of this study is to investigate the acute changes in liver fat content in response to a fixed carbohydrate restriction (i.e.
- Conditions
- NAFLD, Overweight and Obesity, Metabolic Syndrome, Diabetes
- Trial name
- FixedCarb (NCT05643521)
- Testing
- Dietary composition of macronutrients and calories
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Non-alcoholic Steatohepatitis, Liver Diseases
Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI
This is a prospective observational study which will recruit up to 100 paediatric participants over a period of 30 months to determine whether MRI is as accurate at detecting, distinguishing, and monitoring liver disease as…
- Conditions
- Non-alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses, Autoimmune Hepatitis
- Trial name
- Kids4LIFe (NCT03198104)
- Testing
- MRI
- Where
- Poland
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Perspectum
Non-alcoholic Fatty Liver Disease, Renal Function Impairment
Analysis of Renal Impairment Characteristics and High-Risk Factors in Chronic Hepatitis B Patients on Long-Term Oral Nucleos(t)Ide Analogues
This is a single-center retrospective observational study. A total of 300 patients with non-alcoholic fatty liver disease treated in our hospital will be included.
- Trial name
- NCT07730905
- Testing
- Long-term oral nucleos(t)ide analogs antiviral therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Foshan Hospital of Traditional Chinese Medicine
NASH - Nonalcoholic Steatohepatitis
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or…
- Trial name
- MAESTRO-NASH (NCT03900429)
- Testing
- MGL-3196, Liver Biopsy
- Where
- 247 sites in United States, Australia and 14 more
- Volunteers
- 1,759 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Lysosomal Acid Lipase Deficiency
Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D). Eligible participants received once-weekly infusions of sebelipase alfa for up to 3 years.
- Trial name
- NCT02193867
- Testing
- Sebelipase Alfa
- Where
- 5 sites in United States, Finland and 2 more
- Volunteers
- 10 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Type 2 Diabetes, Prediabetes
Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative Stress
"The goal of this work is to critically test the hypothesis that there exists a different profile of bile acids (BAs) in patient with type 2 diabetes mellitus (T2DM) compared with normal controls.
- Conditions
- Type 2 Diabetes, Prediabetes, Non-alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02650830
- Where
- South Korea
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Nonalcoholic Fatty Liver Disease
The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects
A two-part study for NAFLD subjects with normal liver functions and in general good health to be treated with CM-101 or matching placebo and NAFLD/NASH Activity Score (NAS) < 3 that are in general good health and have normal…
- Trial name
- NCT06044467
- Testing
- Anti-human CCL24 monoclonal antibody (CM-101) - Part One, Anti-human CCL24 monoclonal antibody (CM-101) - Part Two
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- ChemomAb Ltd.
NASH - Nonalcoholic Steatohepatitis
Evaluation of an Endoscopic Sutured Gastroplasty in Patients With NonAlcoholic Steatohepatitis (NASH) and Fibrosis.
Nonalcoholic fatty liver disease (NAFLD) is a spectrum of liver diseases characterized by liver steatosis which can, in a minority of patients, progress to nonalcoholic steatohepatitis (NASH), fibrosis, and ultimately…
- Trial name
- ENDONASH (NCT04653311)
- Testing
- Endomina®
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Erasme University Hospital
Sleep Apnea Syndrome, Nonalcoholic Steatohepatitis
Impact of nCPAP Treatment on Liver Function in Patients With Sleep Apnea Syndrome and Nonalcoholic Steatohepatitis
This study aims to evaluate the impact of nasal continuous positive airway pressure (nCPAP) treatment on liver enzymes in patients with sleep apnea syndrome and nonalcoholic steatohepatitis.
- Trial name
- NCT00152711
- Testing
- nCPAP
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Angers
Type 2 Diabetes Mellitus With Complication
Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease
Type 2 diabetes mellitus (T2DM) is always accompanied with nonalcoholic fatty liver disease (NAFLD).This prospective, randomized controlled intervention study was designed to reveal the potential clinical application and…
- Trial name
- NCT05422092
- Testing
- Canagliflozin, Pioglitazone
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Visceral Steatosis, Hiv
Characterization of Visceral Adiposity in HIV Mono-infected Patients With NAFLD
To determine the distribution of visceral fat in people living with HIV (PLHIV) with NAFLD by clinical anthropometric indicators (wais-to-hip ratio), lipid accumulation product (waist circumference and triglycerides) and…
- Conditions
- Visceral Steatosis, Hiv, NAFLD
- Trial name
- Theratech (NCT05359471)
- Testing
- Bone densitometry, Questionnaires, Review of medical chart
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Evaluate the Physiological Stability of NIS4 Biomarker Between the Fed and Fasting State in Patients With the Target Condition (NAFLD)
Evaluation of the Physiological Stability Variability and Robustness of NIS4
Patients at higher risk of progression to cirrhosis and clinical deleterious outcomes are those that have a high grade of necroinflammation together with significant fibrosis.
- Trial name
- NCT06159257
- Testing
- Blood test
- Where
- France
- Volunteers
- 50 people
- Sponsor
- CerbaXpert
Nonalcoholic Fatty Liver Disease, Liver Steatosis
Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis
Nowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year by year, which has become an important public health problem in China.
- Conditions
- Nonalcoholic Fatty Liver Disease, Liver Steatosis, Liver Fibrosis
- Trial name
- NCT03386890
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Friendship Hospital
Type 2 Diabetes With Non-alcoholic Fatty Liver (NAFLD)
Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone
In this study, the investigators investigate beneficial effects of ipragliflozin, newly developted SGLT2 inhibitor, on reduction in visceral fat area and degree of fatty liver in subjects with T2DM when added to metformin and…
- Trial name
- NCT02875821
- Testing
- Ipragliflozin, metformin with pioglitazone
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Yonsei University
Steatohepatitis, Nonalcoholic
The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis
The aim of the current study is to evaluate the safety and efficay of Montelukast in treatment of patients with fatty liver disease.
- Trial name
- NCT04080947
- Testing
- Control group, Montelukast group
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Sadat City University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.